Literature DB >> 9098887

Remodeling domain interfaces to enhance heterodimer formation.

Z Zhu1, L G Presta, G Zapata, P Carter.   

Abstract

An anti-p185HER2/anti-CD3 humanized bispecific diabody was previously constructed from two cross-over single-chain Fv in which YH and VL domains of the parent antibodies are present on different polypeptides. Here this diabody is used to evaluate domain interface engineering strategies for enhancing the formation of functional heterodimers over inactive homodimers. A disulfide-stabilized diabody was obtained by introducing two cysteine mutations, VL L46C and VH D101C, at the anti-p185HER2.VL/VH interface. The fraction of recovered diabody that was functional following expression in Escherichia coli was improved for the disulfide-stabilized compared to the parent diabody (> 96% versus 72%), whereas the overall yield was > 60-fold lower. Eleven "knob-into-hole" diabodies were designed by molecular modeling of sterically complementary mutations at the two VL/VH interfaces. Replacements at either interface are sufficient to improve the fraction of functional heterodimer, while maintaining overall recoverable yields and affinity for both antigens close to that of the parent diabody. For example, diabody variant v5 containing the mutations VL Y87A:F98M and VH V37F:L45W at the anti-p185HER2 VL/VH interface was recovered as 92% functional heterodimer while maintaining overall recovered yield within twofold of the parent diabody. The binding affinity of v5 for p185HER2 extracellular domain and T cells is eightfold weaker and twofold stronger than for the parent diabody, respectively. Domain interface remodeling based upon either sterically complementary mutations or interchain disulfide bonds can facilitate the production of a functional diabody heterodimer. This study expands the scope of domain interface engineering by demonstrating the enhanced assembly of proteins interacting via two domain interfaces.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9098887      PMCID: PMC2144749          DOI: 10.1002/pro.5560060404

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  15 in total

1.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization.

Authors:  J B Ridgway; L G Presta; P Carter
Journal:  Protein Eng       Date:  1996-07

2.  Construction of heterodimer tyrosyl-tRNA synthetase shows tRNATyr interacts with both subunits.

Authors:  P Carter; H Bedouelle; G Winter
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

3.  Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes.

Authors:  J W Ponder; F M Richards
Journal:  J Mol Biol       Date:  1987-02-20       Impact factor: 5.469

4.  "Diabodies": small bivalent and bispecific antibody fragments.

Authors:  P Holliger; T Prospero; G Winter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

5.  Regeneration of active enzyme by formation of hybrids from inactive derivatives: implications for active sites shared between polypeptide chains of aspartate transcarbamoylase.

Authors:  E A Robey; H K Schachman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

6.  Thermodynamic analysis of an antibody functional epitope.

Authors:  R F Kelley; M P O'Connell
Journal:  Biochemistry       Date:  1993-07-13       Impact factor: 3.162

Review 7.  Toward the production of bispecific antibody fragments for clinical applications.

Authors:  P Carter; J Ridgway; Z Zhu
Journal:  J Hematother       Date:  1995-10

8.  The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer.

Authors:  B M Fendly; C Kotts; D Vetterlein; G D Lewis; M Winget; M E Carver; S R Watson; J Sarup; S Saks; A Ullrich
Journal:  J Biol Response Mod       Date:  1990-10

9.  Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation.

Authors:  Z Zhu; P Carter
Journal:  J Immunol       Date:  1995-08-15       Impact factor: 5.422

10.  A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.

Authors:  U Brinkmann; Y Reiter; S H Jung; B Lee; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 12.779

View more
  15 in total

Review 1.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

Review 2.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

Review 3.  Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

Authors:  Christian Klein; Claudio Sustmann; Markus Thomas; Kay Stubenrauch; Rebecca Croasdale; Jürgen Schanzer; Ulrich Brinkmann; Hubert Kettenberger; Jörg T Regula; Wolfgang Schaefer
Journal:  MAbs       Date:  2012-08-27       Impact factor: 5.857

Review 4.  Designing immunotoxins for cancer therapy.

Authors:  Christopher A Pennell; Heidi A Erickson
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

5.  Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.

Authors:  Marcus P Kelly; F-T Lee; Kiki Tahtis; Barbara E Power; Fiona E Smyth; Martin W Brechbiel; Peter J Hudson; Andrew M Scott
Journal:  Cancer Biother Radiopharm       Date:  2008-08       Impact factor: 3.099

6.  The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3.

Authors:  X Y Pei; P Holliger; A G Murzin; R L Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

7.  Nanocell targeting using engineered bispecific antibodies.

Authors:  Karin Taylor; Christopher B Howard; Martina L Jones; Ilya Sedliarou; Jennifer MacDiarmid; Himanshu Brahmbhatt; Trent P Munro; Stephen M Mahler
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 8.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

Review 9.  Design and applications of bispecific heterodimers: molecular imaging and beyond.

Authors:  Haiming Luo; Hao Hong; Sarah P Yang; Weibo Cai
Journal:  Mol Pharm       Date:  2014-04-28       Impact factor: 4.939

10.  Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface.

Authors:  Jin Hong Kim; Dong Hyun Song; Suk-Jun Youn; Ji Won Kim; Geunyoung Cho; Sun Chang Kim; Hayyoung Lee; Mi Sun Jin; Jie-Oh Lee
Journal:  Sci Rep       Date:  2016-09-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.